Since December 2019, an outbreak of coronavirus disease 2019 (COVID-19) which initially
occurred in the city of Wuhan, located in China's Hubei province, spread around the world …

Latest evidences from literature suggest that SARS-CoV-2 disease 2019 (COVID-19) is
commonly complicated with coagulopathy and that disseminated intravascular coagulation …

Background A relatively high mortality of severe coronavirus disease 2019 (COVID‐19) is
worrying, and the application of heparin in COVID‐19 has been recommended by some …

The novel coronavirus infection (COVID-19) is caused by the new coronavirus SARS-CoV-2
and is characterized by an exaggerated inflammatory response that can lead to severe …

SARS-CoV-2 causes a phenotype of pneumonia with diverse manifestation, which is termed
as coronavirus disease 2019 (COVID-19). An impressive high transmission rate allows …

Abstract Coronavirus disease 2019 (COVID‐19) is associated with significant
hypercoagulability. However, despite prophylactic anticoagulation, critically ill patients with …

The novel coronavirus, SARS-CoV-2, is causing a global pandemic of life-threatening
multiorgan disease, called COVID-19. Accumulating evidence indicates that patients with …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative
pathogen of a new infectious disease, coronavirus disease 2019 (COVID-19), that first …

2. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients
with severe novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (6): 1421-1424. 3 …

Introduction Emerging evidence points to an association between severe clinical
presentation of COVID-19 and increased risk of thromboembolism. One-third of patients …